ArticleHealth science reports2025
Clinical and Hematological Manifestation of Dengue Patients in 2022 Outbreak: A Tertiary Care Hospital-Based Cross-Sectional Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Leukopenia and thrombocytopenia in dengue patients: a cross-sectional study from a tertiary hospitals in Koshi Province, Nepal.BMC infectious diseases · 2025Article
- Clinical spectrum and risk factors of severe dengue infection: findings from the 2023 dengue outbreak in Bangladesh.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Dengue is a mosquito-borne viral disease that frequently causes seasonal outbreaks in Bangladesh, particularly during the monsoon months from June to September. Recent outbreaks have shown significant shifts in clinical manifestations, including changes in the timeframe and serotype mixing. This study focused on the clinical and hematological profiles of patients during the 2022 outbreak, which was notably severe. Methods: This quantitative cross-sectional study at Dhaka Medical College and Hospital classified 67 dengue-positive patients as having dengue fever (DF), dengue fever with warning signs (DFWS), and severe dengue (SD). Fisher's exact test, Pearson's chi-squared test, and Wilcoxon rank-sum test were conducted for statistical analysis using the R software (version 4.2), with significance established at Results: Predominantly male patients (76%) aged 21-40 (63%) and middle-class patients from Dhaka (57%) formed the majority. Most patients (45%) lacked a regular drainage system. Laboratory tests showed 63% NS1 antigen (nonspecific antigen 1) positivity, and 16% tested positive for both NS1 and IgM (Immunoglobulin M). Symptoms included headache (84%), retroorbital pain (51%), joint pain (75%), myalgia (72%), vomiting (75%), abdominal pain (69%), diarrhea (39%), and shock (48%). Thrombocytopenia was present in 61% of patients, with 79% showing elevated hematocrit (HCT) levels. Pedal edema, pleural effusion, and ascites were observed in DF and DFWS cases, while SD cases exhibited distinct HCT level variations. Conclusion: Accurate clinical and laboratory assessments are vital for the treatment and prediction of dengue outcomes in Bangladesh, given the severe manifestations of dengue shock syndrome (DSS). It is characterized by headache, muscle pain, thrombocytopenia, anemia, leukopenia, and potential neurological complications or mortality. Severe cases involve critical plasma leakage, leading to DSS with fluid accumulation, respiratory distress, and potential multiorgan involvement. Enhancing physician awareness regarding dengue case detection and management, along with routine dengue testing, are recommended for early diagnosis and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.